title: Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease.
abstract: BACKGROUND
  Acute chest syndrome (ACS) is a frequent cause of hospitalization and mortality in children with sickle cell disease. Transfusion is often required to prevent respiratory failure and treatment with dexamethasone may reduce the length of admission and the need for transfusions. We performed a retrospective cohort study to evaluate risk factors for readmission and prolonged hospitalization after different treatments for ACS.
  
  
  METHODS
  We identified patients <22 years of age hospitalized with ACS at Johns Hopkins Hospital from January 1998 to April 2004 using the hospitals discharge database and by reviewing dictated summaries.
  
  
  RESULTS
  We identified 65 patients with 129 episodes of ACS (mean age 12.5 years, range 1.2-21.9 years). Thirty-nine episodes were treated with corticosteroids and 51 with transfusions. Patients were readmitted within 14 days after 23 episodes (18%). Readmission was strongly associated with report of an inhaler or nebulizer at home [odds ratio (OR) 6.0, P < 0.05], diastolic BP at 48 hr (OR 1.8 per 10 mm increase, P<0.01), corticosteroids (OR 20, P < 0.005), or transfusion (OR 0.03, P < 0.05). Treatment with corticosteroids alone (P < 0.05) and older age (P < 0.001) were associated with longer hospitalization.
  
  
  CONCLUSIONS
  These results demonstrate a greatly elevated independent risk of readmission after ACS in children with asthma and after treatment with corticosteroids and a protective effect of transfusion. Although dexamethasone has documented efficacy for reducing the duration of ACS, the substantial risk of readmission for pain should limit its use.
authors.affiliation: Division of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. jstrous1@jhmi.edu
authors.forename: John J
authors.initials: JJ
authors.lastname: Strouse
authors.forename: Clifford M
authors.initials: CM
authors.lastname: Takemoto
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Keefer
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Kato
authors.forename: James F
authors.initials: JF
authors.lastname: Casella
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D001249:Asthma / Q000188:drug therapy; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D008171:Lung Diseases / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D010359:Patient Readmission / Q000706:statistics & numerical data*; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012120:Respiration Disorders / Q000188:drug therapy; D012189:Retrospective Studies; D015996:Survival Rate; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D003907:Dexamethasone; D011239:Prednisolone; D011241:Prednisone